Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid. - 2Figure out How to Plan for Your Web-based Degree monetarily
- 3Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- 4Experience Unrivaled Sound: Top Speakers You Really want to Hear
- 5Figure out How to Pick a Crematorium: Key Contemplations.
- Relish the World: Notable Caf\u00e9s You Really want to Attempt
- 5 Language Learning Applications
- 'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Astonishing Deserts All over The Planet You Really want To Visit
- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- The World's Dazzling Regular Miracles
